APOLLOMICS, INC. Predicine, Inc. announced a collaboration with Apollomics, Inc. This collaboration aims to advance the development of PredicineCARE, a blood cell-free DNA (cfDNA) next-generation sequencing (NGS) assay, to identify non-small cell lung cancer (NSCLC) patients who may benefit from targeted therapy. PredicineCARE was granted Breakthrough Device Designation (BDD) from the U.S. Food and Drug Administration on August 23, 2022. PredicineCARE is a comprehensive, NGS assay that interrogates point mutations/indels, fusions, amplifications, and deletions in key cancer-associated genes using cfDNA from liquid biopsy samples such as blood and urine.
PredicineCARE Blood cfDNA Assay: The PredicineCARE Blood cfDNA assay is a targeted NGS test that enables detection of genomic alterations, including single nucleotide variants (SNVs), insertions and deletions (Indel), fusions, and copy number variations in cfDNA.
